Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its key diabetes and obesity drugs. What Happened: As reported by Reuters on Sunday, at least 15 Chinese drugmakers are working on generic versions of Novo Nordisk’s drugs Ozempic and Wegovy. The patent for the active ingredient in these drugs is set to expire in China in 2026. Novo Nordisk, a Danish pharmaceutical company, is currently embroiled in a legal battle over the patent in China. An adverse court ruling could lead to an earlier loss of patent…
